<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05069896</url>
  </required_header>
  <id_info>
    <org_study_id>18139</org_study_id>
    <secondary_id>I6T-MC-AMBX</secondary_id>
    <nct_id>NCT05069896</nct_id>
  </id_info>
  <brief_title>A Study to Compare Two Formulations of Mirikizumab (LY3074828) in Healthy Participants</brief_title>
  <official_title>A Bioequivalence Study of Injections of Mirikizumab Solution Using Investigational 1-mL and 2-mL Pre-Filled Syringes and Investigational 1-mL and 2-mL Autoinjectors in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to compare the amount of mirikizumab that gets into the&#xD;
      blood stream and how long it takes the body to get rid of it, when given as a solution&#xD;
      formulation via manual prefilled syringe or autoinjector. The information about any adverse&#xD;
      effects experienced will be collected and the tolerability of mirikizumab will also be&#xD;
      evaluated.&#xD;
&#xD;
      Screening is required within 28 days prior to the enrolment. For each participant, the total&#xD;
      duration of the clinical trial will be about 17 weeks including screening.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 5, 2021</start_date>
  <completion_date type="Anticipated">March 23, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 23, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab</measure>
    <time_frame>Predose up to 85 days postdose</time_frame>
    <description>PK: Cmax of Mirikizumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Mirikizumab</measure>
    <time_frame>Predose up to 85 days postdose</time_frame>
    <description>PK: AUC[0-∞] of Mirikizumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Mirikizumab</measure>
    <time_frame>Predose up to 85 days postdose</time_frame>
    <description>PK: AUC[0-tlast] of Mirikizumab</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">216</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Mirikizumab - Prefilled Syringe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mirikizumab administered by subcutaneous injection (SC) via a prefilled syringe (PFS) at 3 different injection sites (arm, thigh, and abdomen).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mirikizumab - Autoinjector</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mirikizumab administered by SC via an autoinjector (AI) at 3 different injection sites (arm, thigh, and abdomen).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirikizumab Prefilled Syringe</intervention_name>
    <description>Administered SC by prefilled syringe</description>
    <arm_group_label>Mirikizumab - Prefilled Syringe</arm_group_label>
    <other_name>LY3074828</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirikizumab Autoinjector</intervention_name>
    <description>Administered SC by autoinjector</description>
    <arm_group_label>Mirikizumab - Autoinjector</arm_group_label>
    <other_name>LY3074828</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are overtly healthy males or non-pregnant females of childbearing or non-childbearing&#xD;
             potential&#xD;
&#xD;
          -  Have body mass index (BMI) within the range 18.0 to 32.0 kg/m2 (inclusive)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Must not show evidence of active or latent tuberculosis (TB)&#xD;
&#xD;
          -  Must not have received live vaccine(s) (including attenuated live vaccines and those&#xD;
             administered intranasally) within 8 weeks of screening, or intend to during the study&#xD;
&#xD;
          -  Must not have been treated with steroids within 1 month of screening, or intend to&#xD;
             during the study&#xD;
&#xD;
          -  Must not have had a serious infection, or have been hospitalized or have received IV&#xD;
             antibiotics for an infection within 12 weeks prior to Day 1&#xD;
&#xD;
          -  Must not be immunocompromised&#xD;
&#xD;
          -  Must not have received treatment with biologic agents (e.g. monoclonal antibodies,&#xD;
             including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior&#xD;
             to Day 1&#xD;
&#xD;
          -  Must not have clinically significant multiple or severe drug allergies, or intolerance&#xD;
             to topical corticosteroids, or severe post treatment hypersensitivity reactions&#xD;
&#xD;
          -  Must not have had lymphoma, leukemia, or any malignancy within the past 5 years except&#xD;
             for basal cell or squamous epithelial carcinomas of the skin that have been resected&#xD;
             with no evidence of metastatic disease for 3 years&#xD;
&#xD;
          -  Must not have had breast cancer within the past 10 years&#xD;
&#xD;
          -  Must not have significant allergies to humanized monoclonal antibodies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@Lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>LabCorp CRU, Inc.</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>386-366-6400</phone>
    </contact>
    <investigator>
      <last_name>Hugh A Coleman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>QPS</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65802</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>417-831-2048</phone>
    </contact>
    <investigator>
      <last_name>Donald Burkindine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Covance Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>469-513-6727</phone>
    </contact>
    <investigator>
      <last_name>Jeanelle L Kam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 1, 2021</verification_date>
  <study_first_submitted>October 1, 2021</study_first_submitted>
  <study_first_submitted_qc>October 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirikizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

